Sorafenib With Capecitabine and Oxaliplatin for Advanced or Metastatic Hepatocellular Carcinoma
Status:
Unknown status
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
HCC is an aggressive, largely chemo-resistant cancer with a poor prognosis, currently there
is no effective systemic chemotherapy for HCC. Epidermal growth factor receptor (EGFR) and
vascular endothelial growth factor (VEGF) are both overexpressed in HCC and thought to
contribute to tumor development. Oxaliplatin in combination with other chemotherapies or
biologic agents have been shown to be an effective and safe treatment in advanced HCC
patients.
Sorafenib, an oral multi-kinase inhibitor, blocks tumor cell proliferation by targeting
multiple growth factor pathways and also exerts an anti-angiogenic effect. Clinically, single
agent Sorafenib has been shown to have some efficacy in patients with advanced HCC and the
primary result of prolonged overall survival seems to have been achieved in the phase III
trial.